US FDA panel to look at dextromethorphan abuse
This article was originally published in Scrip
Executive Summary
The US FDA's drug safety/risk management advisory panel will meet on 14 September to discuss the abuse potential of the cough suppressant dextromethorphan. The committee will discuss the drug's public health benefits and risks in prescription and over-the-counter products.